Form 8-K AbbVie Inc. For: Apr 03

Go back to Form 8-K AbbVie Inc. For: Apr 03

AbbVie (ABBV) issues updated guidance

April 3, 2025 4:15 PM UTC

AbbVie (NYSE: ABBV):

Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final... More